Molecular Partners and AstraZeneca Announce Collaboration on Molecular Partners' Ongoing Oncology Clinical Study with MP0250 in EGFR-Mutated NSCLC

Apr 11 2018

ZURICH-SCHLIEREN, Switzerland—Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that Molecular Partners and AstraZeneca (LON: AZN) will collaborate on Molecular Partners’ ongoing phase 1b/2 clinical study of MP0250 with osimertinib (Tagrisso®) for the treatment of patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) pre-treated with osimertinib. Under the collaboration, AstraZeneca will supply osimertinib (Tagrisso®) required for the clinical study. The clinical study is planned to enroll approx. 40 patients and is taking place in the United States. 

“We are delighted to welcome AstraZeneca as collaboration partner for our second phase 2 study of MP0250. This underlines the growing interest in MP0250 and nicely documents the potential value of MP0250 in EGFR-mutated NSCLC,” said Dr. Andreas Harstrick, Chief Medical Officer at Molecular Partners.

MP0250 offers the possibility of targeting two main tumor escape pathways by blocking both hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) simultaneously while continued treatment with osimertinib suppresses EGFR-mutated NSCLC tumor cells.

Osimertinib is a third generation, irreversible EGFR-TKI designed to inhibit both EGFR-sensitising and EGFR T790M-resistance mutations, with clinical activity against CNS metastases, which demonstrated significant benefit in untreated EGFR-mutated NSCLC patients in a global phase 3 trial last year. Osimertinib is currently marketed globally, as Tagrisso®, for the treatment of locally advanced or metastatic EGFR T790M NSCLC.

The clinical study1 consists of two parts: the dose-escalation phase (Part A), to establish a safe recommended dose for MP0250 in combination with osimertinib. In the subsequent treatment expansion phase (Part B), patients will be further evaluated for efficacy and safety.

1 identifier NCT03418532

Financial Calendar
April 18, 2018 Annual General Meeting
April 26, 2018 Q1 2018 Management Statement
August 30, 2018 Publication of 2018 Half-year Results
November 01, 2018 Q3 2018 Management Statement